Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Purpose of kinsenoside in preparation of medicine for relieving cognitive dysfunction

A technology of cognitive dysfunction and clematis glycosides, applied in the directions of drug delivery, drug combination, pharmaceutical formulation, etc., can solve the problems of unsatisfactory prognosis of patients, decreased quality of life of patients, and loss of self-care ability of patients.

Active Publication Date: 2019-12-20
福建金兰厚普生物科技有限公司
View PDF6 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

With the aggravation of the course of the disease, cognitive dysfunction causes these patients to gradually lose their ability to take care of themselves, the quality of life of the patients is significantly reduced, and it brings a great burden to the family members
At present, there is no drug that can effectively treat cognitive dysfunction clinically, the prognosis of patients is not ideal, and the rehabilitation effect is poor
[0003] Clematis glucoside is a chemical component extracted from Clematis clematis of Orchidaceae. Pharmacological studies have shown that it has the functions of lowering blood sugar, lowering blood fat, protecting liver and improving osteoporosis, etc., but it has not been found yet. Reports of any effect on cognitive impairment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Purpose of kinsenoside in preparation of medicine for relieving cognitive dysfunction
  • Purpose of kinsenoside in preparation of medicine for relieving cognitive dysfunction
  • Purpose of kinsenoside in preparation of medicine for relieving cognitive dysfunction

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Example 1 Experiment of improving learning and cognitive ability of dementia model mice with auroside

[0034] Scopolamine is used to prepare a dementia model, which is a very commonly used model for drug-prepared animal models of Alzheimer's disease. As of November 2, 2019, in the PUBMED database, there are 1,620 articles using this method to prepare dementia models; for example, the SCI journal paper "A novel chalcone derivative as Nrf2 activator attenuates learning and memory impairment in a scopolamine-induced mousemodel". The model targets cholinergic neurons, which can simulate the symptoms of decreased learning and memory ability caused by the decrease in the activity of cholinergic neurons in Alzheimer's disease, effectively causing cognitive decline in animals, thereby simulating the symptoms of Alzheimer's disease patients. Cognitive impairment status.

[0035] Grouping and administration: 3-month-old C57 mice were randomly divided into blank group, model g...

Embodiment 2

[0044] Example 2 Auroside improves the learning and memory ability of severe depression model mice

[0045]The severe depression model was prepared by Chronic Unpredictable Mild Stress (CUMS). This method is the most commonly used method for preparing severe depression models in this field. As of November 2, 2019, at least 539 papers have been retrieved in the PUBMED database to prepare severe depression models; for details, see the SCI paper "The enriched environment ameliorates chronic unpredictable mild stress-induced depressive-like behaviors and cognitive impairment by activating the SIRT1 / miR-134 signaling pathway in hippocampus". The severe depression model prepared by the method has the characteristics of good stability and high repeatability, and can successfully and stably cause animals to be in a severe depression state, and the cognitive function is obviously decreased.

[0046] Grouping and administration: 3-month-old C57 mice were randomly divided into blank g...

Embodiment 3

[0054] Example 3-Auroside improves cognitive impairment caused by ischemia-reperfusion

[0055] The ischemia-reperfusion model was prepared by the middle cerebral artery occlusion method, which is a commonly used model in this field and widely used. For example, at least 129 research papers were retrieved in the PUBMED database using this method to prepare ischemia-reperfusion-induced cognition damage model. This model specifically causes local brain tissue ischemia, resulting in unilateral damage to the hippocampus and striatum and other brain regions, resulting in reduced learning and memory abilities of animals, and a significant decline in cognitive function.

[0056] Grouping and administration: 6-month-old C57 mice were randomly divided into blank group, model group, auroside 1 group (20mg / kg) and auroside 2 group (50mg / kg), 15 Only. The blank group and the model group were given intragastric administration of normal saline every day, 200ul / piece; the auroside 1 grou...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a purpose of kinsenoside or a pharmacologically acceptable salt of the kinsenoside in preparation of medicine for relieving cognitive dysfunction. The kinsenoside or the pharmacologically acceptable salt of the kinsenoside can be used for effectively preventing and treating various kinds of cognitive dysfunction diseases.

Description

technical field [0001] The present invention relates to the pharmaceutical use of the compound, in particular to the use of auroside or a pharmaceutically acceptable salt thereof in the preparation of medicines for improving cognitive dysfunction. Background technique [0002] Cognitive dysfunction is a large category of symptoms that cause long-term and continuous decline in cognitive functions such as learning and memory due to various factors. Memory impairment, accompanied by the pathological process of changes such as aphasia, apraxia, agnosia, and alopecia. Clinically, diseases with cognitive impairment as the main symptom mainly include Alzheimer's disease, Parkinson's disease, vascular dementia, post-stroke cognitive impairment, and major depression. These patients are mainly characterized by decreased cognitive abilities such as learning and memory. As the course of the disease worsens, cognitive dysfunction causes these patients to gradually lose their ability to...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61P25/28A61P25/24
CPCA61K9/0056A61K31/7048A61P25/24A61P25/28
Inventor 袁增强潘瑞远廖亚金张海燕
Owner 福建金兰厚普生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com